Medicare Enrolled
Dr. Maryam Afshar, M.D.
Student in an Organized Health Care Education/Training Program · San Diego, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Afshar from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Afshar?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Afshar
Dr. Maryam Afshar is a student in an organized health care education/training program specialist in San Diego, CA, with 13 years of NPI registration. Based on federal Medicare data, Dr. Afshar performed 4,128 Medicare services across 2,174 unique beneficiaries.
Between the years covered by Open Payments, Dr. Afshar received a total of $7,583 from 33 pharmaceutical and/or device companies across 338 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in student in an organized health care education/training program. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Afshar is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 13 years in practice
▲ Top 4% volume in CA
$7,583 industry payments
Medicare Practice Summary
Medicare Utilization ↗4,128
Medicare services
Top 4% in CA for student in an organized health care education/training program
2,174
Unique beneficiaries
$61
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~318 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Destruction of precancerous skin growths, 2-14 This procedure involves the removal or destruction of two to fourteen precancerous skin lesions. It is performed to eliminate abnormal skin cells that have the potential to develop into cancer. |
1,602 | $6 | $28 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
685 | $93 | $350 |
| Destruction of precancerous skin growth, 1 Removal of a single precancerous skin growth. This procedure destroys abnormal skin cells to prevent them from developing into cancer. |
495 | $41 | $266 |
| Skin biopsy, tangential A procedure to remove a sample of the first identified skin growth for laboratory examination. |
263 | $73 | $414 |
| Destruction of skin growths (warts/lesions), 1-14 This procedure involves the removal or destruction of one to fourteen skin growths. It is a minor surgical intervention performed on the skin surface. |
251 | $95 | $458 |
| Destruction of 15 or more precancerous skin growths This procedure involves the removal or destruction of fifteen or more precancerous skin lesions. It is performed to treat abnormal skin cells that have the potential to develop into cancer. |
151 | $142 | $674 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
129 | $71 | $248 |
| Additional skin growth biopsy Removal of a sample of an additional skin growth for laboratory examination. This code is used for each extra lesion biopsied during the same session. |
72 | $45 | $205 |
| Surgical removal of skin cancer, 2.1-3.0 cm This procedure involves the surgical excision of a cancerous skin growth located on the body, arms, or legs. The size of the removed tissue measures between 2.1 and 3.0 centimeters. |
63 | $123 | $1,097 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
63 | $78 | $305 |
| Destruction of skin growth, 15 or more growths | 59 | $111 | $533 |
| Complicated wound repair, scalp/arms/legs, 2.6-7.5 cm A complex surgical procedure to close a wound on the scalp, arms, or legs that measures between 2.6 and 7.5 centimeters in length. |
48 | $366 | $1,699 |
| Complicated wound repair of trunk, 2.6-7.5 cm A surgical procedure to close a complex wound on the trunk that measures between 2.6 and 7.5 centimeters in length. |
45 | $326 | $1,594 |
| Complicated wound repair, 2.6-7.5 cm A complex surgical procedure to close a wound measuring between 2.6 and 7.5 centimeters on areas such as the face, neck, hands, or feet. |
43 | $411 | $1,872 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
39 | $41 | $156 |
| Skin tag removal, 1-15 tags This procedure involves the removal of one to fifteen skin tags. It is a minor surgical intervention to excise these benign growths from the skin. |
32 | $53 | $357 |
| Destruction of cancerous skin growth, 2.1-3.0 cm This procedure involves the removal or destruction of a cancerous skin lesion measuring between 2.1 and 3.0 centimeters located on the trunk, arms, or legs. |
30 | $140 | $765 |
| Skin cancer removal, face/ears/eyes/nose/lips, 2.1-3.0 cm Surgical removal of a cancerous skin growth from the face, ears, eyelids, nose, lips, or mouth. The procedure involves excising a lesion measuring between 2.1 and 3.0 centimeters. |
23 | $138 | $1,235 |
| Surgical removal of skin cancer, 2.1-3.0 cm Surgical excision of a cancerous skin growth measuring 2.1 to 3.0 centimeters from the scalp, neck, hands, feet, or genitals. |
18 | $130 | $1,163 |
| New patient office visit, 15-29 minutes An initial office visit for a new patient lasting 15 to 29 minutes. This code is used when the total time spent on the date of the encounter meets this duration threshold. |
17 | $59 | $201 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$7,583
Total received (2018-2024)
Avg $1,083/year across 7 years
Top 5% in CA for student in an organized health care education/training program
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
33
Companies
338
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,278 (96.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$305 (4.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,287
2023
$2,631
2022
$439
2021
$326
2020
$122
2019
$440
2018
$337
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GENZYME CORPORATION
$368
ABBVIE INC.
$341
Incyte Corporation
$332
LEO Pharma Inc.
$253
E.R. Squibb & Sons, L.L.C.
$252
Lilly USA, LLC
$243
Janssen Biotech, Inc.
$170
Novartis Pharmaceuticals Corporation
$151
SUN PHARMACEUTICAL INDUSTRIES INC.
$149
Arcutis Biotherapeutics, Inc.
$147
Galderma Laboratories, L.P.
$141
Amgen Inc.
$138
Boehringer Ingelheim Pharmaceuticals, Inc.
$109
Regeneron Healthcare Solutions, Inc.
$99
PFIZER INC.
$82
Dermavant Sciences, Inc.
$80
Smith+Nephew, Inc.
$63
Acera Surgical, Inc.
$63
Verrica Pharmaceuticals Inc.
$37
ConvaTec Inc.
$32
Almirall LLC
$21
Organogenesis Inc.
$17
Top 3 companies account for 31.7% of 2024 payments
All-time payments by company (2018-2024) ›
GENZYME CORPORATION
$1,048
Incyte Corporation
$767
Janssen Biotech, Inc.
$680
Lilly USA, LLC
$653
Amgen Inc.
$542
LEO Pharma Inc.
$396
ABBVIE INC.
$377
E.R. Squibb & Sons, L.L.C.
$340
Regeneron Healthcare Solutions, Inc.
$284
Arcutis Biotherapeutics, Inc.
$248
Sun Pharmaceutical Industries Inc.
$228
Novartis Pharmaceuticals Corporation
$226
Celgene Corporation
$218
SUN PHARMACEUTICAL INDUSTRIES INC.
$172
AbbVie Inc.
$165
Dermavant Sciences, Inc.
$161
Galderma Laboratories, L.P.
$157
PFIZER INC.
$147
Boehringer Ingelheim Pharmaceuticals, Inc.
$135
Janssen Scientific Affairs, LLC
$100
Acera Surgical, Inc.
$97
AbbVie, Inc.
$67
Smith+Nephew, Inc.
$63
Ortho Dermatologics, a division of Bausch Health US, LLC
$54
Merz North America, Inc.
$46
Almirall LLC
$42
Verrica Pharmaceuticals Inc.
$37
VYNE Pharmaceuticals Inc.
$32
ConvaTec Inc.
$32
Integra LifeSciences Corporation
$25
Organogenesis Inc.
$17
Bioventus LLC
$14
Helsinn Therapeutics (U.S.), Inc.
$13
Top 3 companies account for 32.9% of all-time payments
Associated products mentioned in payments ›
ADBRY · AMZEEQ · AQUACEL AG+ EXTRA · CIBINQO · COSENTYX · Cordran · DERMATITIS - DISEASE · DUOBRII · DUPIXENT · EBGLYSS · EUCRISA · HUMIRA · Humira · ILUMYA · INNOVAMATRIX AC · Ilumya · Integra · JUBLIA · Klisyri · OPZELURA · Otezla · REMICADE · RINVOQ · Restrata Wound Matrix · SKYRIZI · SPEVIGO · STRAVIX · Skyrizi · Sotyktu · TALTZ · TREMFYA · Tremfya · VALCHLOR · VTAMA · Winlevi · XEOMIN · YCANTH · Zoryve
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 5% for student in an organized health care education/training program in CA.
Geographic Context
Student in an organized health care education/training programs within 10 mi
3,586
Per 100K population
109.2
County median income
$102,285
Nearest hospital
VA SAN DIEGO HEALTHCARE SYSTEM
1.7 mi
1.7 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Afshar is a clinical cardiology specialist, with above-average Medicare volume (top 4% in CA), with low-engagement industry engagement in the top 5% of CA peers.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Afshar experienced with destruction of precancerous skin growths, 2-14?
Based on Medicare claims data, Dr. Afshar performed 1,602 destruction of precancerous skin growths, 2-14 services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Afshar receive payments from pharmaceutical companies?
Yes. Dr. Afshar received a total of $7,583 from 33 companies across 338 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Afshar's costs compare to other student in an organized health care education/training programs in San Diego?
Dr. Afshar's average Medicare payment per service is $61. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Afshar) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Student In An Organized Health Care Education/training Programs in San Diego
Browse student in an organized health care education/training programs in San Diego ranked by procedure volume and transparency data.
Highest volume
Top Student In An Organized Health Care Education/training Programs in CA
Student in an organized health care education/training programs ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Student In An Organized Health Care Education/training Programs in CA
Which CA student in an organized health care education/training programs receive the most from drug and device companies.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology